503A vs 503B Pharmacies: A Plain Guide, Updated for 2026

Last updated: August 18, 2026. Originally published November 1, 2025. This update covers what changed for 503B outsourcing facilities in 2026, the 2026 warning letters, how distributors differ from compounders, and how state licensing works for each.

This article is general education, not medical advice. Talk with a licensed clinician and pharmacist about your own treatment.

A 503A pharmacy compounds medication for one named patient after receiving that person's prescription, and it is licensed by state pharmacy boards. A 503B outsourcing facility registers with the FDA, can make larger batches, must follow manufacturing standards, and is not required to be a licensed pharmacy at all (FDA). Neither one makes FDA-approved drugs. The big 2026 change is that the FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the list of bulk ingredients 503B facilities may use (FDA).

Who This Helps

Maybe someone told you your GLP-1 comes from a compounding pharmacy and you want to understand what that means in more detail. Maybe you're comparing providers who throw these numbers (503A or 503B) around, or you turned over a vial and found a company name you'd never heard of. Any of those, you're in the right place.

What Is a Compounding Pharmacy?

A compounding pharmacy prepares a medication rather than dispensing it in the form a manufacturer shipped. A pharmacist combines or alters ingredients to fill a specific prescription, which is how patients get a liquid version of a pill, a formulation without an allergen, or a strength that is not commercially made.

Because these preparations do not go through the FDA's pre-market approval process, federal law treats them separately under two sections of the Federal Food, Drug, and Cosmetic Act, numbered 503A and 503B (FDA). The names 503B and 503A are just the sections of the statute that govern them, nothing more mysterious than that. For the broader background, our explainer on how compounding pharmacies are regulated goes deeper.

Compounder, Dispenser, Distributor: What Is the Difference?

These words get used interchangeably all the time, including by people who should know better, and they actually describe different legal roles. Laid out in the same shape, the differences are easier to keep straight.

A compounding pharmacy prepares the medication. It makes or alters the preparation itself, and under 503A it does so against a prescription for a named patient.
A dispensing pharmacy hands the medication to you. It fills your prescription and its name and address appear on your prescription label. It may or may not be the same business that compounded the product.
A wholesale distributor moves medication between businesses. It buys and sells or transfers prescription drugs to pharmacies, clinics, and other distributors rather than to patients, and it operates under federal supply-chain tracing rules (FDA).
A third-party logistics provider only handles storage and shipping. It does not take ownership of the medication, and both distributors and these providers report annually to the FDA (FDA).

What this means for you: more than one of these businesses can touch a single vial. That is why the company printed on your vial and the pharmacy named on your paperwork can legitimately differ. Our guide on why a pharmacy may not appear licensed in your state walks through how to check each one.

Find a provider in your state

Answer a few questions and see live pricing from the providers that ship where you live.

Get started

What Does a 503A Pharmacy Do?

A 503A pharmacy compounds for an individual. It can only prepare a medication after receiving a prescription for a specific, named person, and its compounded preparations are not FDA-approved drugs (FDA).

The practical characteristics that follow from that:

Licensed and inspected primarily by state boards of pharmacy, with FDA authority still applying to certain federal requirements.
Exempt from federal drug manufacturing standards, and instead expected to meet United States Pharmacopeia compounding standards, chiefly chapters 795 for nonsterile and 797 for sterile preparations (USP).
Cannot produce large batches in advance for general office use and resale.
Typically the pharmacy that both compounds and dispenses directly to you.

What Does a 503B Outsourcing Facility Do?

A 503B outsourcing facility operates more like a small manufacturer. It registers with the FDA, may compound in larger batches, and must comply with current good manufacturing practice requirements (FDA).

Two facts about these facilities surprise almost everyone, and both come straight from the FDA. First, an outsourcing facility "is not required to be a licensed pharmacy," though compounding must occur by or under the direct supervision of a licensed pharmacist. Second, these facilities "may or may not obtain prescriptions for identified individual patients" (FDA).

That first point explains a dead end a lot of people hit. If the name on your vial belongs to a 503B outsourcing facility, searching your state's pharmacy license database can turn up nothing at all, which feels alarming and usually isn't. You'd check the FDA's registered outsourcing facility list instead (FDA).

One more caution the FDA states plainly: registration "does not mean that the facility is making FDA-approved drugs and it does not mean it is in compliance with current good manufacturing practice." Registration means the agency received the required information. Marketing that presents "FDA registered" as equivalent to "FDA approved" is describing two different things.

What Changed for 503B Facilities in 2026?

The most consequential change is still pending, and it goes to the heart of compounded GLP-1s. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, stating that it "did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances" (FDA). The notice published in the Federal Register the following day (Federal Register).

As of this update the comment period has closed and no final determination has been issued, so this is a proposal only at this point. If finalized, it would remove the bulk-substance pathway 503B facilities have used for these ingredients.

Liraglutide sits differently from the other two. Drug shortage status is a separate pathway from the bulks list, and liraglutide supply has been reported as constrained more recently than semaglutide or tirzepatide, which came off the shortage list earlier. A generic liraglutide is also now approved and on the market (Teva). Shortage entries change, so check the current status in the FDA's shortage database rather than relying on any article (FDA Drug Shortages database).

To summarize the future of 503Bs in the world of compounded GLP-1s: the national GLP-1 shortage ended and the FDA's temporary enforcement flexibility for compounders expired, so compounding these drugs now rests on a documented patient-specific reason rather than on supply (FDA). Our post on what changed in compounding covers that transition.

What Do the 2026 Warning Letters Show?

FDA registration and inspection are constantly working, and 2026 produced a steady run of enforcement against outsourcing facilities. One example is a warning letter issued to an Ohio outsourcing facility in March 2026 (FDA warning letter), and another went to a facility in April 2026 (FDA warning letter). Several more were published in a batch that same month.

The recurring theme in these letters is sterility. They describe drug products intended to be sterile as having been prepared, packed, or held under insanitary conditions, which under federal law renders a product adulterated. Some 2026 letters also cited products that were subpotent or quality systems that were inadequate. You can read any individual letter yourself, which is the most reliable way to see what a specific facility was cited for (FDA).

What this means for you: read enforcement two ways at once. It shows oversight is active, which is the point of registering with the FDA. It also shows that being a 503B facility is not a guarantee of quality on its own. You can search any facility by name in the FDA's warning letter database (FDA).

How Does State Licensing Work for Each?

Licensing is where the two types diverge most, and where patients most often get confused.

A 503A pharmacy shipping to you needs a license in your state. States generally require an out-of-state pharmacy to hold a non-resident license or permit before mailing a prescription to a resident. Wyoming requires any pharmacy outside the state that ships, mails, or delivers a dispensed prescription drug to a patient there to hold a non-resident license (Wyoming Board of Pharmacy rules), and Florida requires non-resident registration plus licensure in the pharmacy's home state (Florida Board of Pharmacy). All requirements vary by state, so yours may be different.
A 503B outsourcing facility registers federally, and state requirements still apply separately. FDA registration is a federal step and does not replace state authorization. Because these facilities are not required to be licensed pharmacies, what a given state requires of them varies, which is why the FDA list is the right place to verify the facility itself (FDA).
A wholesale distributor holds a different license entirely. Distributor licensing is its own category under state law and federal supply-chain rules, and it authorizes moving product between businesses rather than dispensing to patients (FDA).

To check any of these, start at your own state's board of pharmacy, which you can reach through the national directory of boards (NABP). Search by legal business name, trade name, street address, and license number, since a brand name often differs from the licensed entity.

Is One Type Better Than the Other?

Neither is categorically safer, and the honest answer depends on what you are weighing. A 503B facility is required to meet manufacturing standards and is subject to federal inspection, which brings process controls a small pharmacy may not have, though as the warning letters show, being subject to those standards is not the same as meeting them. A 503A pharmacy prepares your specific prescription, which is the entire point when a prescriber has documented that you need something different from the commercial product.

What matters more than the number is whether the operation is licensed, transparent about what it makes, and willing to answer questions. Both types are governed by regulating organizations. Neither is the same as an unlicensed seller shipping vials with no pharmacist involved, which our guides to grey-market peptides and GLP-1s versus peptides cover.

Will You Deal With the Pharmacy Directly?

Usually not. A telehealth platform routes your prescription to a partner pharmacy, that pharmacy ships to you, and you may never speak with anyone there. You can still ask which pharmacy filled it, whether it's a 503A pharmacy or a 503B facility, and where it's licensed. If a provider won't answer that, you can consider if that means it’s outside your safety zone.

For the full sequence of checks to run before you pay, see our guide to evaluating telehealth and compounded GLP-1 providers. You can also compare providers, including compounding options and the pharmacies they work with, using the GLP Winner provider survey.

What Should You Ask?

Is my medication compounded or an FDA-approved product?
Which pharmacy or facility does the actual compounding vs distributing, and is it a 503A pharmacy or a 503B outsourcing facility?
What is the documented clinical reason this is being compounded for me specifically?
Is the dispensing pharmacy licensed in my state, and what is its license number?
What testing is done for potency, purity, and sterility, and can I see documentation?
What is the beyond-use date, and how should I store it?
Has the facility received an FDA warning letter, and if so, what was resolved?

If your formulation includes added ingredients, our post on additives in compounded GLP-1s covers what they do and the allergy questions worth raising. For the wider peptide picture, see the 2026 FDA peptide reclassification.

Final Takeaway

The difference comes down to scale and oversight. A 503A pharmacy compounds your individual prescription under state licensing, and a 503B facility makes batches under FDA registration and manufacturing rules.

Neither produces an FDA-approved drug, and FDA registration is not FDA approval. A 503B facility does not even have to be a licensed pharmacy, which is why a state license search can come back empty.

The 2026 story is a pending FDA proposal that would remove semaglutide, tirzepatide, and liraglutide from the bulk substances 503B facilities may use, plus a steady run of sterility-related warning letters.

Ask which pharmacy, ask why compounded, and verify the license. Those three questions will do more for you than memorizing any section number, and you can get through all three in about ten minutes.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

Frequently Asked Questions

What is the difference between a 503A and a 503B pharmacy?

A 503A pharmacy compounds medication for one named patient after receiving that person's prescription and is licensed by state pharmacy boards. A 503B outsourcing facility registers with the FDA, can compound larger batches, must follow manufacturing standards, and is not required to be a licensed pharmacy.

Does FDA registered mean FDA approved?

No. The FDA says registration means only that the agency received the required information, and that it does not mean the facility makes FDA-approved drugs or complies with current good manufacturing practice. Compounded preparations are not FDA-approved products either way.

Why can't I find my pharmacy in my state's license database?

A common reason is that the name belongs to a 503B outsourcing facility, which is not required to be a licensed pharmacy, so you would check the FDA's registered outsourcing facility list instead. Other causes are searching a brand name rather than the licensed business name, or searching the wrong state's board.

Can 503B facilities still compound semaglutide and tirzepatide?

That is the pending question. In April 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list, finding no sufficient clinical need. The comment period has closed and no final determination has issued, so the proposal is not yet a rule.

What is the difference between a compounding pharmacy and a distributor?

A compounding pharmacy prepares the medication, a dispensing pharmacy fills your prescription and appears on your label, and a wholesale distributor moves prescription drugs between businesses rather than to patients. More than one of these can be involved with a single vial, which is why names can differ.